ModRNA Doesn’t Prevent/Reduce Myocarditis following COVID19 Hospitalization

Risk of Myocarditis and other AESI > Risk of COVID Hospitalizations (Part 19)

A retrospective cohort study (CardioCOVID-Gemelli) conducted using data from all patients over 18 years of age admitted to Fondazione Policlinico A. Gemelli IRCCS Hospital in Rome for COVID19 disease between March 2021 and February 2022 found that out of 1,019 patients treated for COVID19 145 patients suffered myocardial injury. Out of the 352 vaccinated patients admitted 61 suffered myocardial injury with high sensitivity cardiac troponin levels greater than 56 nanograms/Liter, with the majority of recipients (35) receiving one or more Pfizer doses. Among the several positive predictors of elevated risk of myocardial injury including advanced age, hypertension, renal impairment, COPD, and Chronic Kidney disease vaccination status at zero doses was not one of them. In fact, between the 3 tertiles the study divided patients into by age, the COVID shots were only found to reduce the risk of myocardial injury from infection in the last tertile of seniors over 76 years of age and elevated risk of myocardial injury after infection in the lower tertiles ( 60-75 years and less than 60 years) although it was only statistically significant in the first tertile at the 0.05 alpha level. However, the authors conclude that vaccination status was not a statistically significant predictor of myocardial injury following hospitalization in the overall study population.

This study undercuts the common mainstream risk benefit analysis that assumes any observed higher rate of myocarditis after infection than injection in hospital data proves that modRNA therapeutics reduced the risk of myocarditis. However, as I have repeatedly noted in this series with numerous studies much larger than this is one, that assumption is not only untrue when applied to specific demographics such as males between 12-17 years of age and males under 40 in general, but it also assumes that modRNA therapeutics prevent myocarditis following infection severe enough to result in hospitalization, as almost all infections in the aforementioned demographics are either mild or asymptomatic. Here the authors note that no studies prior to this one evaluated the incidence and predictors of myocardial injury from infection after the introduction of the COVID19 shots as most start before the introduction when comparing rates of myocarditis after infection to rates of myocarditis after injection.